Zovirax — Competitive Intelligence Brief

Zovirax (ACYCLOVIR) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]. Area: Immunology.

marketed Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC] Purine nucleoside phosphorylase Immunology Small molecule

Target snapshot

Zovirax (ACYCLOVIR) — Ligand Pharms. Acyclovir works by mimicking a building block of DNA to prevent the herpes virus from replicating.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zovirax TARGET	ACYCLOVIR	Ligand Pharms	marketed	Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]	Purine nucleoside phosphorylase	1982-01-01
Immucillin H	FORODESINE	Mundi Pharma	marketed		Purine nucleoside phosphorylase	2017-01-01
Aciclovir	Aciclovir	Assistance Publique Hopitaux De Marseille	marketed		Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase
ACYC	ACYC	Ligand Pharms	marketed		Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase
Valtrex	valaciclovir	GSK	marketed	Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor		1995-01-01
Famvir	FAMCICLOVIR	Novartis	marketed	Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]		1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC] class)

1. Ligand Pharms · 1 drug in this class
2. Novartis · 1 drug in this class